Search

Your search keyword '"Broijl, A"' showing total 9 results
Start Over Author "Broijl, A" Publisher nature publishing group
9 results on '"Broijl, A"'

1. Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands

Author

Mirian Brink, Monique C. Minnema, Otto Visser, Mark-David Levin, Eduardus F. M. Ward Posthuma, Annemiek Broijl, Pieter Sonneveld, Marjolein van der Klift, Wilfried W. H. Roeloffzen, Matthijs Westerman, Cleo R. van Rooijen, Paul A. F. Geerts, Sonja Zweegman, Niels W. C. J. van de Donk, and Avinash G. Dinmohamed

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2022
Full Text
View/download PDF

2. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study

Author

Mirian Brink, Kaz Groen, Pieter Sonneveld, Monique C. Minnema, Annemiek Broijl, Avinash G. Dinmohamed, Ellen van der Spek, Mark-David Levin, Paula F. Ypma, Esther de Waal, Eduardus F. M. Ward Posthuma, Sonja Zweegman, and Niels W. C. J. van de Donk

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at risk for EM. This population-based study aimed to assess trends in EM and risk factors for EM among MM patients diagnosed in the Netherlands. All MM patients, newly diagnosed between 1989 and 2018, were identified in the Netherlands Cancer Registry. Patients were categorized into three calendar periods (1989–1998, 1999–2008, 2009–2018) and into five age groups (≤65, 66–70, 71–75, 76–80, >80 years). EM was defined as death by any cause ≤180 days post-diagnosis. We included 28,328 MM patients (median age 70 years; 55% males). EM decreased from 22% for patients diagnosed in 1989–1998 to 13% for patients diagnosed in 2009–2018 (P 70 years. Therefore, novel strategies should be explored to improve the outcome of patients at risk for EM.

Published
2021
Full Text
View/download PDF

3. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study

Author

Mark-David Levin, Paula F. Ypma, Sonja Zweegman, Monique C. Minnema, Pieter Sonneveld, Esther G. M. de Waal, Eduardus F. M. Posthuma, Mirian Brink, Kaz Groen, Niels W.C.J. van de Donk, Ellen van der Spek, Avinash G Dinmohamed, Annemiek Broijl, Hematology, Public Health, and CCA - Cancer Treatment and quality of life

Subjects
Adult, Male, medicine.medical_specialty, Population, MEDLINE, Newly diagnosed, Article, Age groups, SDG 3 - Good Health and Well-being, Internal medicine, Humans, Medicine, In patient, Registries, education, Multiple myeloma, RC254-282, Aged, Netherlands, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Age Factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Hematology, Middle Aged, medicine.disease, Prognosis, Cancer registry, Population based study, Oncology, Risk factors, Female, Multiple Myeloma, business, Follow-Up Studies
Abstract

Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at risk for EM. This population-based study aimed to assess trends in EM and risk factors for EM among MM patients diagnosed in the Netherlands. All MM patients, newly diagnosed between 1989 and 2018, were identified in the Netherlands Cancer Registry. Patients were categorized into three calendar periods (1989–1998, 1999–2008, 2009–2018) and into five age groups (≤65, 66–70, 71–75, 76–80, >80 years). EM was defined as death by any cause ≤180 days post-diagnosis. We included 28,328 MM patients (median age 70 years; 55% males). EM decreased from 22% for patients diagnosed in 1989–1998 to 13% for patients diagnosed in 2009–2018 (P 70 years. Therefore, novel strategies should be explored to improve the outcome of patients at risk for EM.

Published
2021

4. Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Brink, Mirian, Minnema, Monique C, Visser, Otto, Levin, Mark-David, Posthuma, Eduardus F M Ward, Broijl, Annemiek, Sonneveld, Pieter, van der Klift, Marjolein, Roeloffzen, Wilfried W H, Westerman, Matthijs, van Rooijen, Cleo R, Geerts, Paul A F, Zweegman, Sonja, van de Donk, Niels W C J, Dinmohamed, Avinash G, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Brink, Mirian, Minnema, Monique C, Visser, Otto, Levin, Mark-David, Posthuma, Eduardus F M Ward, Broijl, Annemiek, Sonneveld, Pieter, van der Klift, Marjolein, Roeloffzen, Wilfried W H, Westerman, Matthijs, van Rooijen, Cleo R, Geerts, Paul A F, Zweegman, Sonja, van de Donk, Niels W C J, and Dinmohamed, Avinash G

Published
2022

5. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Brink, Mirian, Groen, Kaz, Sonneveld, Pieter, Minnema, Monique C, Broijl, Annemiek, Dinmohamed, Avinash G, van der Spek, Ellen, Levin, Mark-David, Ypma, Paula F, de Waal, Esther, Posthuma, Eduardus F M Ward, Zweegman, Sonja, van de Donk, Niels W C J, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Brink, Mirian, Groen, Kaz, Sonneveld, Pieter, Minnema, Monique C, Broijl, Annemiek, Dinmohamed, Avinash G, van der Spek, Ellen, Levin, Mark-David, Ypma, Paula F, de Waal, Esther, Posthuma, Eduardus F M Ward, Zweegman, Sonja, and van de Donk, Niels W C J

Published
2021

6. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial

Author

Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J., Sonneveld, P., Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J., and Sonneveld, P.

Abstract

The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR) = 0.76, 95% confidence interval (95% CI) of 0.65-0.89, P = 0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR = 0.89, 95% CI: 0.74-1.08, P = 0.24). The incidence of SPM were similar between the two arms (7% each, P = 0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size >= 10%) and renal impairment at baseline (serum creatinine > 2 mg dl(-1)) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR = 1.02, P = 0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.

Published
2018

7. Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial

Author

Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, and Sonneveld, P

Published
2018

8. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

Author

Externen Hematologie, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P, Externen Hematologie, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, and Sonneveld, P

Published
2018

9. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease.

Author

van Andel H, Kocemba KA, de Haan-Kramer A, Mellink CH, Piwowar M, Broijl A, van Duin M, Sonneveld P, Maurice MM, Kersten MJ, Spaargaren M, and Pals ST

Subjects
Case-Control Studies, Deubiquitinating Enzyme CYLD, Humans, Multiple Myeloma genetics, NF-kappa B metabolism, Transfection, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins metabolism, Multiple Myeloma metabolism, Multiple Myeloma pathology, Tumor Suppressor Proteins deficiency, Wnt Signaling Pathway
Abstract

Deletion or mutation of the gene encoding the deubiquitinating enzyme CYLD is a common genomic aberration in multiple myeloma (MM). However, the functional consequence of CYLD loss and the mechanism underlying its putative role as a tumor suppressor gene in the pathogenesis of MM has not been established. Here, we show that CYLD expression is highly variable in myeloma cell lines and primary MMs and that low CYLD expression is associated with disease progression from monoclonal gammopathy of undetermined significance to MM, and with poor overall and progression free-survival of MM patients. Functional assays revealed that CYLD represses MM cell proliferation and survival. Furthermore, CYLD acts as a negative regulator of NF-κB and Wnt/β-catenin signaling and loss of CYLD sensitizes MM cells to NF-κB-stimuli and Wnt ligands. Interestingly, in primary MMs, low CYLD expression strongly correlated with a proliferative and Wnt signaling-gene expression signature, but not with an NFκB target gene signature. Altogether, our findings identify CYLD as a negative regulator of NF-κB and Wnt/β-catenin signaling in MM and indicate that loss of CYLD enhances MM aggressiveness through Wnt pathway activation. Thus, targeting the Wnt pathway could be a promising therapeutic strategy in MM with loss of CYLD activity.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results